Claritev Corporation, the NYSE-listed healthcare cost-containment platform formerly known as MultiPlan, sits mid-pivot from a leveraged roll-up into an AI-enabled vertical services company. The pivot runs under a multi-year program called Vision 2030. Q2 2026 revenue of $257.5M marks the fifth straight quarter of top-line growth. It supports an upgraded full-year revenue range of $1.0B-$1.02B. Operating income of $23.4M reflects early traction. A $59.2M net loss tied to interest expense shows that the equity story remains hostage to leverage. The cash earnings power of the platform continues to expand underneath the GAAP loss.
The thesis is straightforward. Claritev converts the savings it identifies for payers into recurring fees. The legacy 2020 SPAC financing loads the income statement with non-cash amortization of $171.8M for the first half. The same period carries $199.8M of interest expense that swamps operating profit. Vision 2030 spending in the first half, plus antitrust-related legal expenses, drag on near-term GAAP earnings. Adjusted EBITDA of $155.8M, up 1.1% year-over-year, illustrates the gap between cash earnings power and the reported loss. Updated guidance confirms management expects that gap to narrow.
The risk asymmetry favors a patient long. The Class A shares trade at $38.43. That price sits inside a fifty-two week range of $11.50-$74.07. Enterprise value sits near $5.35B. That implies the market still values the platform at roughly 17x trailing Adjusted EBITDA. With a DOJ antitrust grand jury proceeding formally closed in July, the existential regulatory cloud has lifted. The remaining civil investigative demand and provider-side litigation create execution friction, not survival risk. Each named catalyst maps onto a specific dollar variable in the equity value. That map is what the equity investor is buying.